Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N 1) platinum in patients with metastatic solid tumors

Richard L. Theriault; I. A. Cohen; Laura Esparza; C. Kowal; Martin N. Raber

doi:10.1007/bf00685681

Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N 1) platinum in patients with metastatic solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/bf00685681 ◽

1993 ◽

Vol 31 (4) ◽

pp. 333-337 ◽

Cited By ~ 6

Author(s):

Richard L. Theriault ◽

I. A. Cohen ◽

Laura Esparza ◽

C. Kowal ◽

Martin N. Raber

Keyword(s):

Phase I ◽

Solid Tumors ◽

Clinical Evaluation

Phase I trial of bortezomib daily dose: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.2623 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 2623-2623

Author(s):

Rastislav Bahleda ◽

Marie-Cécile Le Deley ◽

Apexa Bernard ◽

Shalini Chaturvedi ◽

Anas Gazzah ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Clinical Evaluation ◽

Phase I Trial ◽

Biological Effects ◽

Pharmacokinetic Profile ◽

Advanced Solid Tumors ◽

Daily Dose

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

Investigational New Drugs ◽

10.1007/s10637-008-9112-9 ◽

2008 ◽

Vol 26 (2) ◽

pp. 159-167 ◽

Cited By ~ 44

Author(s):

Patricia M. LoRusso ◽

Shirish M. Gadgeel ◽

Antoinette Wozniak ◽

Alan J. Barge ◽

Helen K. Jones ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Clinical Evaluation ◽

Vascular Targeting ◽

Vascular Targeting Agent

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-017-0531-3 ◽

2017 ◽

Vol 36 (4) ◽

pp. 619-628 ◽

Cited By ~ 4

Author(s):

Rastislav Bahleda ◽

Marie-Cécile Le Deley ◽

Apexa Bernard ◽

Shalini Chaturvedi ◽

Michael Hanley ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Clinical Evaluation ◽

Phase I Trial ◽

Biological Effects ◽

Pharmacokinetic Profile ◽

Advanced Solid Tumors ◽

Daily Dose

Faculty Opinions recommendation of Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13790.471274 ◽

2006 ◽

Author(s):

Jeffrey Evans

Keyword(s):

Phase I ◽

Solid Tumors ◽

Clinical Evaluation ◽

Vascular Targeting ◽

The Novel ◽

Weekly Administration ◽

Vascular Targeting Agent

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

10.1158/1538-7445.am2013-lb-66 ◽

2013 ◽

Cited By ~ 14

Author(s):

Udai Banerji ◽

Malcolm Ranson ◽

Jan HM Schellens ◽

Taito Esaki ◽

Emma Dean ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Clinical Evaluation ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Two Phase ◽

Multicenter Trials

Phase I Trial and Pharmacokinetics Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70478-0 ◽

2007 ◽

Vol 2007 ◽

pp. 292-293

Author(s):

R.J. Arceci

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Neurofibromatosis Type ◽

Type I ◽

Neurofibromatosis Type I ◽

Farnesyltransferase Inhibitor ◽

Plexiform Neurofibromas ◽

Pharmacokinetics Study

A Phase I Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Case Medical Research ◽

10.31525/ct1-nct04175847 ◽

2019 ◽

Author(s):

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study

Faculty Opinions recommendation of Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14346.471799 ◽

2006 ◽

Author(s):

Jeffrey Evans

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Irreversible Inhibitor ◽

Epidermal Growth

Faculty Opinions recommendation of Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718036740.793483439 ◽

2013 ◽

Author(s):

Antoine Italiano

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase I ◽

Solid Tumors ◽

Oncology Group ◽

Pharmacodynamic Study

Faculty of 1000 evaluation for A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718050520.793482822 ◽

2013 ◽

Author(s):

Burton Eisenberg

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Phase I Study ◽

Pediatric Patients ◽

Deacetylase Inhibitor